Enterprise Value to EBITDA Ratio: Purple Biotech (PPBT)
The price history on the EV/EBITDA chart for Purple Biotech (PPBT), whose operations focus on combating tumors, demonstrates the significance of 0.00, highlighting the biotech's independence from economic cycles. However, regional conflicts may threaten infrastructure and hinder the delivery of drugs abroad. Simultaneously, Purple Biotech (PPBT) is actively developing its scientific potential by testing new therapeutic agents for the treatment of solid neoplasms.
Financial and market metric breakdowns for purple-biotech.com (PPBT)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Purple Biotech|PPBT - Long-Term Liabilities to Equity|Short-Term Debt to Equity Ratio Purple Biotech Ltd.|PPBT - Company Aggregate Debts|Debt to Book Capitalization Ratio Kitov Pharma|PPBT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Purple Biotech|Quick Liquidity purple-biotech.com
- business earnings and investment ratios data:
PPBT - Company Net Income|Projected Future Earnings Purple Biotech|PPBT - Market Cap to Earnings|Projected Price to Earnings Purple Biotech|PPBT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Kitov Pharma|PPBT - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Purple Biotech|PPBT - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months purple-biotech.com|PPBT - Earnings per share growth rate in current year|Expected earnings per share growth for next year Purple Biotech
Fundamental company analysis:PPBT (Purple Biotech Corp)
Purple Biotech focuses on autonomous clinical trials of oncology drugs while maintaining limited partnerships. The Enterprise Value to EBITDA ratio quantifies the debt load and the real value of the issuer's assets. By analyzing the EV/EBITDA chart trend for Purple Biotech, an investor determines the business's resilience to information shocks, distinguishing a temporary correction from a systemic financial crisis.
Key competitors
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|DCTH: Company Value to Operating Income Before Depreciation Ratio|Y-mAbs Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Biosciences Inc AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ARAY (Accuray, Inc.)|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ACTU (actuatetherapeutics.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HURA|EV/EBITDA Multiple TARA|FATE - Company Value to EBITDA|Aadi Bioscience - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TCRX|Champions Oncology Corp - EV/EBITDA Multiple|XBIT: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CVM: EV/EBITDA Multiple|OSTX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics|Company Value to EBITDA Artiva ARTV|Enterprise Value to EBITDA Ratio ANL (Adlai Nortye Ltd.)|Enterprise Value to Operating Income Before Depreciation Ratio VERU|EV/EBITDA Multiple TPST (Tempest Tx)|Xilio Therapeutics Inc (XLO) - Company Value to EBITDA|Enochian BioSciences - EV/EBITDA Multiple|Mural Oncology plc (MURA) - Enterprise Value to EBITDA Ratio|KAPA: EV/EBITDA Multiple|OnKure Therapeutics - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CytoMed Therapeutics Ltd|Curis Corp - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Apollomics, Inc. (APLM)|THAR: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ADVB (Advanced Biomed)|Genprex Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CLDI: Enterprise Value to EBITDA Ratio|sunshinebiopharma.com - Enterprise Value to Operating Income Before Depreciation Ratio|XBIO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio salariuspharma.com|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple BeiGene Ltd.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics, Inc (CKPT)|Elevation Oncology Inc. - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ICAD (iCAD)|IKNA - Enterprise Value to EBITDA Ratio|Notable Labs - EV/EBITDA Multiple|Company Value to EBITDA Viracta Therapeutics|MorphoSys Corp (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NAYA Biosciences Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio AAPGV
